Erschienen in:
07.09.2017 | Letter to the Editor
Optimism and the continued promise of maintenance chemotherapy
verfasst von:
John P. Micha, Bram Goldstein, Maurie Markman
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 4/2017
Einloggen, um Zugang zu erhalten
Excerpt
Advanced stage ovarian cancer is associated with a high incidence of disease progression and an overall 5-year survival rate of approximately 35% [
1]. Patients who obtain a clinical remission in response to debulking surgery and induction platinum-based chemotherapy are regarded as chemo-sensitive and the extent to which they exhibit a sustained platinum free interval favorably impacts their outcome [
2,
3]. Therefore, one may assert that strategies which further conduce the platinum free survival will accord a significant, therapeutic benefit. …